Your browser doesn't support javascript.
loading
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.
Miller, Mark Steven; Allen, Peter J; Brown, Powel H; Chan, Andrew T; Clapper, Margie L; Dashwood, Roderick H; Demehri, Shadmehr; Disis, Mary L; DuBois, Raymond N; Glynn, Robert J; Kensler, Thomas W; Khan, Seema A; Johnson, Bryon D; Liby, Karen T; Lipkin, Steven M; Mallery, Susan R; Meuillet, Emmanuelle J; Roden, Richard B S; Schoen, Robert E; Sharp, Zelton D; Shirwan, Haval; Siegfried, Jill M; Rao, Chinthalapally V; You, Ming; Vilar, Eduardo; Szabo, Eva; Mohammed, Altaf.
Afiliação
  • Miller MS; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.
  • Allen PJ; Division of Surgical Oncology, Duke Cancer Institute, Durham, NC, USA.
  • Brown PH; Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, MD Anderson Cancer Center, Houston, TX, USA.
  • Chan AT; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Clapper ML; Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Dashwood RH; Center for Epigenetics & Disease Prevention, Institute of Biosciences & Technology, Texas A&M Health Science Center, Houston, TX, USA.
  • Demehri S; Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
  • Disis ML; Cancer Vaccine Institute, University of Washington School of Medicine, Seattle, WA, USA.
  • DuBois RN; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
  • Glynn RJ; Division of Preventive Medicine, Brigham & Women's Hospital, Boston, MA, USA.
  • Kensler TW; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Khan SA; Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Johnson BD; Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Liby KT; Department of Pharmacology & Toxicology, Michigan State University, East Lansing, Michigan, NY, USA.
  • Lipkin SM; Division of Gastroenterology and Hepatology, Weill Cornell University, New York, NY, USA.
  • Mallery SR; Department of Oral and Maxillofacial Pathology, College of Dentistry, Ohio State University, Columbus, OH, USA.
  • Meuillet EJ; PHusis Therapeutics, San Diego, CA, USA.
  • Roden RBS; Department of Pathology, Cancer Prevention and Control Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Schoen RE; Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Sharp ZD; Department of Molecular Medicine, University of Texas Science Center at San Antonio, San Antonio, TX, USA.
  • Shirwan H; Department of Child Health and Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA.
  • Siegfried JM; Department of Pharmacology, Masonic Cancer Center, University of Minnesota School of Medicine, Minneapolis, MN, USA.
  • Rao CV; Medical Oncology Center for Cancer Prevention & Drug Development, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • You M; Department of Pharmacology and Toxicology, Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Vilar E; Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, MD Anderson Cancer Center, Houston, TX, USA.
  • Szabo E; Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.
  • Mohammed A; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.
J Cancer Prev ; 26(1): 71-82, 2021 Mar 30.
Article em En | MEDLINE | ID: mdl-33842408
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article